Rigel Reports P-III (FOCUS) Trial Results of Fostamatinib for COVID-19 in High Risk Hospitalized Patients
Shots:
- The P-III (FOCUS) trial evaluates fostamatinib (BID) + SoC vs PBO + SoC in 280 patients with COVID-19 without respiratory failure for 14 days with a follow-up period to Day 60
- The results showed the mean no. of days on oxygen through Day 29 (6.9 vs 9.0 days), a 50% reduction in patient all-cause mortality, mean change from baseline in clinical status score to Day 15 was -2.4 vs -1.9, the median no. of days to first sustained hospital discharge (6 vs 7 days), patients were alive and oxygen-free (85.1% vs 73.4%), no. of days in the ICU (2.2 vs 3.3)
- The safety profile was consistent with prior results with no new safety issues. All prespecified 2EPs were numerically favored fostamatinib
Ref: Rigel | Image: Rigel
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
